Global Radiation Therapy Systems Market Expected to Reach $5.6B by 2020

Although immunotherapy and other cutting-edge technologies have dominated the spotlight in cancer treatment over the last several years, the use of radiation therapy is rapidly increasing as physicians look to this non-invasive, cost-effective treatment to address a broad and growing number of cancers. Valued at nearly $4.3 billion in 2015, the global radiation therapy market is growing at a CAGR of 5.5%, and is projected to reach $5.6 billion by 2020, according to a recent report from Medtech Insight.

Despite advances in cancer prevention, diagnosis and treatment, the number of new cancer cases worldwide is expected to increase 70% over the next 20 years, growing from around 14 million in 2012 to more than 22 million, according to the latest statistics from the World Health Organization. In 2012, roughly 32.6 million people were living with cancer within five years of diagnosis and there were 8.2 million cancer-related deaths.

While much of the recent news in cancer treatment has focused on immunotherapy and other cutting-edge technologies, radiation therapy, surgery...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: June 16–20, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

EnsoData Boosts AI Sleep Tech With $20M Series B Funding, Targets Underdiagnosis Crisis

 
• By 

EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.